Standardization of antifungal susceptibility testing

REFERENCES

• Calhoun D.L., Roberts G.D., Galgiani J.N., Bennett J.E., Feingold D.S., Jorgensen J., Kobayashi G.S., Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. Journal of Clinical Microbiology 1986; 23: 298–301
   PubMed Web of Science ®Google Scholar
• Cook R.A., McIntyre K.A., Galgiani J.N. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrobial Agents and Chemotherapy 1990; 34: 1542–1545
   PubMed Web of Science ®Google Scholar
• Deldicque P. Corrélation entre l'activité in vitro des antifongiques et la réponse in vivo: étude bioclinique. University of Lille. 1984, M. D. Dissertation
   Google Scholar
• Drouhet E., Dupont B., Improvisi L., Viviani M.A., Tortorano A.M. Disc agar diffusion and microplate automatized technics for in vitro evaluation of antifungal agents on yeasts and sporulated pathogenic fungi. In Vitro and In Vivo Evaluation of Antifungal Agents, K. Iwata, H. Vanden Bossche. Elsevier Science Publishers B.V., Amsterdam 1986; 31–49, In
   Google Scholar
• Galgiani J.N. Antifungal susceptibility tests. Antimicrobial Agents and Chemotherapy 1987; 31: 1867–1870
   PubMed Web of Science ®Google Scholar
• Galgiani J.N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M.A., Kerkering T.M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrobial Agents and Chemotherapy 1987; 31: 1343–1347
   PubMed Web of Science ®Google Scholar
• Galgiani J.N., Stevens D.A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrobial Agents and Chemotherapy 1976; 10: 721–728
   PubMed Web of Science ®Google Scholar
• Galgiani J.N., Stevens D.A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrobial Agents and Chemotherapy 1978; 13: 249–254
   PubMed Web of Science ®Google Scholar
• Guinet R., Nerson D., deClosets F., Dubouy-Camet J., Kures L., Marjollet M., Poirot J.L., Ros A., Texier-Maugein J., Volle P.J. Collaborative evaluation in seven laboratories of a standardized micromethod of yeast susceptibility testing. Journal of Clinical Microbiology 1988; 26: 2307–2312
   PubMed Web of Science ®Google Scholar
• Horsburgh C.R., Kirkpatrick C.H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with twenty-one patients. American Journal of Medicine 1983; 74(Suppl. 1B)23S–29S
   PubMedGoogle Scholar
• Kwong-Chung K.J. (1978) Heterothallism vs. self-fertile isolates of Filobasidiella neoformans (Cryptococcus neoformans). Proceedings of the Fourth International Conference on the Mycoses, The black and white yeasts, BrasiliaBrazil, June, 6–81977, 204–213, Scientific Publication No. 356
   Google Scholar
• LaRocco M. Recent developments in antifungal susceptibility testing. Clinical Microbiology Newsletter 1991; 13: 81–85
   Google Scholar
• Maugein J., Fourche J., Mormede M., Marit G. Étude de la sensibilité des levures à 7 antifongiques par une technique standardisée mycototalND chez des malades traités pour hémopathies malignes. Feuillets de Biologie 1989; 30: 41–44
   Google Scholar
• McIntyre K.A., Galgiani J.N. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: Effects of test conditions and relation to in vivo efficacy. Antimicrobial Agents and Chemotherapy 1989; 33: 1095–1100
   PubMed Web of Science ®Google Scholar
• Menard M. Étude mycologique et sensibilité à la 5-FC de 277 souches de levures opportunistes isolées en 1981 à l'hôpital principal de Dakar. Essentiellement de prélevements vaginaux. Médecine d'Afrique Noire 1982; 29: 759–768
   Google Scholar
• Minagawa H., Kitaura K., Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrobial Agents and Chemotherapy 1983; 23: 105–107
   PubMed Web of Science ®Google Scholar
• Morace G., Manzara S., Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy 1991; 37: 23–31
   PubMed Web of Science ®Google Scholar
• Odds F.C., Webster C.E., Abbott A.B. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. Journal of Antimicrobial Chemotherapy 1984; 14: 105–114
   PubMed Web of Science ®Google Scholar
• Ohkawa M., Tokunaga S., Takashima M., Nishikawa T., Hisazumi H., Fujita S., Wheat R.W. In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents. Chemotherapy 1990; 36: 396–402
   PubMed Web of Science ®Google Scholar
• Penali L.K., Kone M., Coco-Agbo B., Faye-Kette Achi H., Kouassi M.T., BoueTan A., Kouakou B. Sensibilité aux antifongiques des sérotypes de Candida albicans isolés à Abidjan (Côte d'Ivoire). Publique Médicine Afrique 1989; 99: 9–13
   Google Scholar
• Pfaller M.A., Burmeister L., Bartlett M.S., Rinaldi M.G. Multicenter evaluation of four methods of yeast inoculum preparation. Journal of Clinical Microbiology 1988; 26: 1437–1441
   PubMed Web of Science ®Google Scholar
• Pfaller M.A., Rinaldi M.G., Galgiani J.N., Bartlett M.S., Body B.A., Espinel-Ingroff A., Fromtling R.A., Hall G.S., Hughes C.E., Odds F.C., Sugar A.M. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy 1990; 34: 1648–1654
   PubMed Web of Science ®Google Scholar
• Polak A. Mode of action of 5-fluorocytosine and 5-fluorouracil in dematiaceous fungi. Sabouraudia 1983; 21: 15–25
   PubMedGoogle Scholar
• Polak A., Ansorg R., Bartmann K., Dermoumi H., Hantschke D., Plempel M., Schär G., Tarbuc M. Multizenter-Studie zur Standardisierung der Empfindlichkeitsbestimmung von Pilzen gegen 5-Fluorocytosin und Amphotericin B. Mykosen 1987; 30: 306–308, 311–314
   PubMedGoogle Scholar
• Polak-Wyss A. Die antimykotische Chemotherapie opportunistischer Pilzinfektionen. Habilitationsschrift vorgelegt der Med. Fakultät der Albert-Ludwigs-Universität. University of Freiburg. 1989
   Google Scholar
• Rockstroh J.K., Hachmann A., Molitor E., Tschubel K., Marklein G., Luster W., Ewig S. A case of AIDS-associated histoplasmosis in Germany. Klinische Wochenschrift 1991; 69: 325–329
   PubMedGoogle Scholar
• Rogers T.E., Galgiani J.N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1986; 30: 418–422
   PubMed Web of Science ®Google Scholar
• Ryley J.F., Wilson R.G., Barrett-Bee K.J. Azole resistance in Candida albicans. Sabouraudia: Journal of Medical and Veterinary Mycology 1984; 22: 53–63
   Google Scholar
• Shadomy S., Pfaller M.A. Laboratory studies with antifungal agents: susceptibility tests and quantitation in body fluids. Manual of Clinical Microbiology5th edn., A. Balows, W.J. Hausler, K.L. Herrmann, H.D. Isenburg, H.J. Shadomy. American Society for Microbiology, Washington, D.C. 1991; 1173–1183, In
   Google Scholar
• Shadomy S., Shadomy H.J. Comparative in vitro antifungal susceptibility studies with 30 serotype A and serotype B isolates of Candida albicans. Diagnostic Microbiology and Infectious Disease 1991; 14: 21–22
   PubMed Web of Science ®Google Scholar
• Speller D.C.E., Cartwright R.Y., Evans E.G.V., Hay R.J., Mackenzie D.W.R., Milne L.J.R., Odds F.C., Warnock D.W., Wingfield H.J. Laboratory methods for flucytosine (5-fluorocytosine). Report of a working Group of the British Society for Mycopathology. Journal of Antimicrobial Agents and Chemotherapy 1984; 14: 1–8
   Web of Science ®Google Scholar
• Stiller R.L., Bennett J.E., Scholer H.J., Wall M., Polak A., Stevens D.A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. Journal of Infectious Diseases 1983; 147: 1070–1077
   PubMed Web of Science ®Google Scholar
• Trancassini M., Ghezzi M.C., Cipriani P., Mancini C., Brenciaglia M.I. Susceptibility of candida species strains to five antifungal agents: comparison between agar dilution and disk diffusion tests. Chemioterapia 1986; 5: 14–17
   PubMedGoogle Scholar
• Van der Auwera P., Ceuppens A.M., Heymans C., Meunier F. In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrobial Agents and Chemotherapy 1986; 29: 997–1004
   PubMed Web of Science ®Google Scholar
• Vernes A., Fruit J. État actuel de la sensibilité des levures du genre Candida vis-à-vis de la 5-fluorocytosine, dans le nord de la France. Bulletin de la Société Française de Mycologie Médicale 1981; 10: 339–342
   Google Scholar
• Weber S. Das Resistenzverhalten von Sprosspilzisolaten aus definierten Probandengruppen gegenüber dem Antimykotikum 5-Flurocytosin. M. D. Dissertation. University of Freiburg. 1991
   Google Scholar
• Werk R., Knothe H. Comparison of agar dilution test, broth dilution test, and broth elution test for assaying susceptibility of Candida spp. Current Microbiology 1984; 10: 173–176
   Web of Science ®Google Scholar
• Whelan W.L. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Critical Reviews in Microbiology 1987; 15: 45–56
   PubMed Web of Science ®Google Scholar